Ketobe 10mg

Tablet
Ketorolac Tromethamine
BENHAM pharmaceuticals

Other Strength:

Alternative:
- Xidolac Meltab 10mg
- WINOP 10mg
- Torax 10mg
- Zeropain 10mg
- Toramax 10mg
- Minolac 10mg
- Analac 10mg
- Ketofast 10mg
- Doltro 10mg
- Xiroket 10mg
- Tolec 10mg
- Toro 10mg
- Ketoroz 10mg
- Lacor 10mg
- Rolac 10mg
- Rolac MDT 10mg



Ketobe
Presentation:
Ketobe tablet: Each film coated tablet contains Ketorolac Tromethamine USP 10 mg.
Description: Ketorolac Tromethamine is a drug of pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs). Chemically it is known as 5 benzoyl -2,3-dihydro-1H-pyrroligine-1-carboxylic acid, compound with 2 - amino-2-(hydroxymethyl)-1,3- propanediol (1:1). Ketorolac Tromethamine inhibits the synthesis of prostaglandin and may be considered as a peripherally acting analgesic. The biological activity of Ketorolac Tromethamine is associated with the S-form.
Pharmacokinetic property of Ketorolac Tromethamine is linear. It is highly protein bound and is largely metabolized in liver. The products of metabolism and some unchanged drugs are excreted in the urine.

Indication:
Ketorolac Tromethamine is indicated for the short-term (<5 days) management of moderate to severe acute post operative pain.

Indication:
Ketorolac Tromethamine is indicated for the short-term (<5 days) management of moderate to severe acute post operative pain.

Dosage & Administration:
Ketobe (Ketorolac Tromethamine) tablets are recommended for short-term use only (up to 7 days) and are not recommended for chronic use. 10mg every 4 to 6 hours as required. Doses exceeding 40mg per day are not recommended. For patients receiving parenteral Ketorolac Tromethamine and who are converted to Ketorolac Tromethamine oral tablets, the total combined daily dose should not exceed 90mg (60mg for the elderly, renally-impaired patients and patients less than 50 kg) and the oral component should not exceed 40mg on the day the change of formulation is made. Patients should be converted to oral treatment as soon as possible.

Side Effect:
Commonly occurring side-effects are nausea, vomiting, gastro-intestinal bleeding, melaena, peptic ulcer, pancreatitis, anxiety, drowsiness, dizziness, headache, hallucinations, excessive thirst, inability to concentrate, insomnia, malaise, fatigue, pruritus, urticaria, skin photosensitivity, Lyell’s syndrome, Stevens Johnson syndrome, flushing, bradycardia, hypertension, palpitations, chest pain, infertility in female, dyspnoea, asthma, pulmonary oedema, fever, injection site pain.

Contraindication:
Ketorolac Tromethamine is contraindicated in patients having hypersensitivity to this drug or other NSAIDs and those patients in whom aspirin or other prostaglandin synthesis inhibitors induce allergic reactions. It is also contraindicated in a history of peptic ulcer or gastro-intestinal bleeding, moderate or severe renal impairment (serum creatinine> 160 micromol/L), a history of asthma. Ketorolac Tromethamine is contra-indicated as prophylactic analgesia before surgery due to inhibition of platelet aggregation and is contra-indicated intra-operatively because of the increased risk of bleeding

Drug Interaction:
Ketorolac Tromethamine should not be used with other NSAIDs or in patients receiving aspirin because of the potential for additive side-effects. Care should be taken when administering Ketorolac Tromethamine with anti-coagulants since co-administration may cause an enhanced anti-coagulant effect. Ketorolac Tromethamine and other non-sterqidal anti-inflammatory drugs can reduce the anti-hypertensive effect of beta-blockers and may inctease the risk of renal impairment when administered concurrently with ACE inhibitors, particularly in volume depleted patients. Caution is advised when methotrexate is administered. Concurrently, since some prostaglandin synthesis inhibiting drugs have been reported to reduce the clearance of methotrexate and thus possibly enhance its toxicity. Probenecid should not be administered concurrently with Ketorolac Tromethamine because it increases in Ketorolac plasma level and half-life. Precaution:
Patients over the age of 65 years may be at a greater risk of experiencing adverse events than younger patients. Ketorolac Tromethamine can cause gastro-interstinal irritation, ulcers or bleeding in patients with or without a history of previous symptoms. Since Ketorolac Tromethamine and its metabolites are excreted primarily by the kidney, patients with moderate to severe impairment of renal function (serum creatinine greater than 160 micromol/L) should not receive. Fluid retention and oedema have been reported with the use of Ketorolac Tromethamine.

Use in Pregnancy & Lactation:
Safety in human pregnancy has not been established. Ketorolac Tromethamine has been detected in human milk at low levels. ketorolac Tromethamine is therefore contraindicated during pregnancy, labour or delivery, or in mothers who are breast feeding.

Overdose:
Overdosage of Ketorolac Tromethamine may cause abdominal pain, peptic ulcers which healed after discontinuation of doses. Metabolic acidosis has been reported following intentional overdosage.

Storage:
Store in a cool and dry place, protect from light & moisture. Keep out of the reach of children.

এই পাতাটি ৩৪৭ বার দেখা হয়েছে